ATE522502T1 - Therapeutisches mittel gegen atemwegserkrankungen,das ein 4-hydroxypiperidinderivat als wirkstoff enthält - Google Patents

Therapeutisches mittel gegen atemwegserkrankungen,das ein 4-hydroxypiperidinderivat als wirkstoff enthält

Info

Publication number
ATE522502T1
ATE522502T1 AT03811921T AT03811921T ATE522502T1 AT E522502 T1 ATE522502 T1 AT E522502T1 AT 03811921 T AT03811921 T AT 03811921T AT 03811921 T AT03811921 T AT 03811921T AT E522502 T1 ATE522502 T1 AT E522502T1
Authority
AT
Austria
Prior art keywords
halogenated
hydrogen
respiratory diseases
lower alkyl
active ingredient
Prior art date
Application number
AT03811921T
Other languages
English (en)
Inventor
Yasushige Akada
Kazuyuki Matsuura
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Application granted granted Critical
Publication of ATE522502T1 publication Critical patent/ATE522502T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
AT03811921T 2002-11-25 2003-11-25 Therapeutisches mittel gegen atemwegserkrankungen,das ein 4-hydroxypiperidinderivat als wirkstoff enthält ATE522502T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002341251 2002-11-25
PCT/JP2003/015005 WO2004048326A1 (ja) 2002-11-25 2003-11-25 ４−ヒドロキシピペリジン誘導体を有効成分とする呼吸器疾患治療剤

Publications (1)

Publication Number Publication Date
ATE522502T1 true ATE522502T1 (de) 2011-09-15

Family

ID=32375845

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03811921T ATE522502T1 (de) 2002-11-25 2003-11-25 Therapeutisches mittel gegen atemwegserkrankungen,das ein 4-hydroxypiperidinderivat als wirkstoff enthält

Country Status (7)

Country Link
US (1) US7494987B2 (de)
EP (1) EP1568688B1 (de)
JP (1) JP4544999B2 (de)
AT (1) ATE522502T1 (de)
AU (1) AU2003302416A1 (de)
CA (1) CA2507509A1 (de)
WO (1) WO2004048326A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008179541A (ja) * 2005-05-02 2008-08-07 Mochida Pharmaceut Co Ltd 神経因性疼痛治療薬
CA2635550A1 (en) 2006-01-04 2007-07-12 Cipla Limited Process and intermediate for preparation of donepezil
US20080242650A1 (en) * 2007-03-26 2008-10-02 Jean-Louis Thomas Oral contraceptive regimen
MY162507A (en) 2009-06-29 2017-06-15 Incyte Holdings Corp Pyrimidinones as pi3k inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
UA107818C2 (en) * 2009-12-23 2015-02-25 Medicis Pharmaceutical Corp Usa Alkyl amino pyrimidine derivatives as antagonists district h4-histamine receptors
CA2796311A1 (en) 2010-04-14 2011-10-20 Incyte Corporation Fused derivatives as pi3k.delta. inhibitors
WO2012087881A1 (en) 2010-12-20 2012-06-28 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US9108984B2 (en) * 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) * 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
RS55737B1 (sr) 2011-09-02 2017-07-31 Incyte Holdings Corp Heterociklilamini kao inhibitori pi3k
EP2797915B1 (de) * 2011-12-27 2016-07-13 Ironwood Pharmaceuticals, Inc. 2-Benzyl-3-(Oxazol/Thiazol)-5-(Pyrimidin-2-yl)-1(H)-Pyrazol-Derivate als Stimulatoren der löslichen Guanylat-Cyclase (sGC) zur Behandlung von Bluthochdruck und Herzversagen
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US10047095B2 (en) * 2014-09-17 2018-08-14 Ironwood Pharmaceuticals, Inc. sGC stimulators
CR20210055A (es) 2015-02-27 2021-04-27 Incyte Corp SALES DE IHNIBIDOR DE PI3K Y PROCESOS DE PREPARACIÓN (Divisional 2017-0389)
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
CN115215787A (zh) * 2021-04-19 2022-10-21 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508724A (en) * 1984-02-03 1985-04-02 A. H. Robins Company, Inc. Aryloxymethylpyrrolidinols and piperidinols having antidepressant, antiarrhythmic or hypotensive activity
MY104343A (en) * 1987-11-23 1994-03-31 Janssen Pharmaceutica Nv Novel pyridizinamine deravatives
PL169884B1 (pl) 1991-07-17 1996-09-30 Pfizer Sposób wytwarzania nowych pochodnych 2-(4-hydroksypiperydyno)-1-alkanolowych PL PL PL
US5696267A (en) 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
ES2202481T3 (es) * 1996-10-28 2004-04-01 Schering Corporation Arilalquilaminas sustituidas como antagonistas de neuroquinina.
ID29137A (id) 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
JP2000103782A (ja) * 1998-07-31 2000-04-11 Kyorin Pharmaceut Co Ltd 環状アミン誘導体及びその製造方法
EP1182193A4 (de) 1999-04-09 2002-09-11 Mochida Pharm Co Ltd Medikamente gegen neuropathische schmerzen
CA2369691A1 (en) 1999-04-09 2000-10-19 Yutaka Miyazaki 4-hydroxypiperidine derivatives having antiarrhythmic effect
WO2002022572A2 (en) 2000-09-11 2002-03-21 Sepracor, Inc. Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission)
JP2005097120A (ja) * 2000-10-06 2005-04-14 Mochida Pharmaceut Co Ltd ４−ヒドロキシピペリジン誘導体の非潮解性塩
US6956046B2 (en) 2001-05-25 2005-10-18 Mochida Pharmaceutical Co., Ltd. 4-hydroxypiperidine derivatives having analgesic activity

Also Published As

Publication number Publication date
EP1568688B1 (de) 2011-08-31
EP1568688A1 (de) 2005-08-31
US20060040985A1 (en) 2006-02-23
US7494987B2 (en) 2009-02-24
WO2004048326A1 (ja) 2004-06-10
CA2507509A1 (en) 2004-06-10
JPWO2004048326A1 (ja) 2006-03-23
AU2003302416A1 (en) 2004-06-18
EP1568688A4 (de) 2008-12-17
JP4544999B2 (ja) 2010-09-15

Similar Documents

Publication Publication Date Title
ATE522502T1 (de) Therapeutisches mittel gegen atemwegserkrankungen,das ein 4-hydroxypiperidinderivat als wirkstoff enthält
NO20064297L (no) Aminoalkoholforbindelse
BR0316586A (pt) Derivados de diidropirano indol-3, 4-dione e derivados de 3-ácido oxoacético 2-hidroximetilindol substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
PE20011348A1 (es) Agentes antivirales de imidazopiridina e imidazopimiridina
DE60322359D1 (de) Imidazopyridinderivate als kinaseinhibitoren
NO20021401L (no) Kinazolinforbindelser og farmasöytiske preparater som inneholder slike forbindelser
DE69331843T2 (de) Xanthine-Derivate als Antidepressiva
NO20064705L (no) Nye farmasoytiske preparater omfattende agonister av tyroidreseptoren
ATE390415T1 (de) Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung
ATE537830T1 (de) Nicotinamid derivate und ihre verwendung als therapeutika
DE60324155D1 (de) Indol-3-carbinol metaboliten als chemotherapeutische und chemopräventive wirkstoffen
DE60303954D1 (de) Chinolyl-propylpiperidinderivate und deren verwendung als antimikrobielle wirkstoffe
DE60236719D1 (de) Purinderivate als antagonisten an purinergen rezeptoren
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
NO20060146L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
DE69838662D1 (de) Morphinanderivate und ihre medizinische Anwendung
AR045959A1 (es) Derivados de pirazolo- e imidazo-pirimidina
ATE300543T1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
BR0315777A (pt) Uso de derivados de piperazina como antagonistas ccr1
GEP20053626B (en) Substituted 8-Arylquinoline Phosphodiesterase-4 Inhibitors, Pharmaceutical Composition Containing Them and Use Thereof
DE60202682D1 (de) Chinoline derivate und ihre anwendung als antitumor agentien
FI945458A (fi) Parannettuja antiandrogeenejä
DE69226931T2 (de) Guanidinothiazolederivate und ihre Anwendung als H2-Rezeptor-Antagonisten
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
DE502004007387D1 (de) Triazolverbindungen und ihre therapeutische verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties